Euro
USD
British Pound
NULL
Product Description
CPI-17 (phospho-T38) polyclonal Antibody | BS4780 | Bioworld
Host: Rabbit
Reactivity: Human,Mouse,Rat
Application: WB IHC
Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200
Background: CPI-17 is a phosphorylation-dependent inhibitory protein for smooth muscle myosin phosphate. CPI-17 was originally identified as a PKC-potentiated inhibitory protein of protein phosphatase-1, which is dominantly expressed in smooth muscle. Phosphorylation at Threonine 38, in vitro, by PKC or Rho-kinase enhances the inhibitory potency toward myosin phosphatase. CPI-17 is also phosphorylated at Threonine 38 by protein kinase N and might be involved in the calcium sensitization of smooth muscle contraction as a downstream effector of Rho and/or arachidonic acid. CPI-17 is dually phosphorylated at Serine 12 and Threonine 38 by a MYPT-associated kinase, M110 kinase.
Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity: p-CPI-17 (T38) polyclonal Antibody detects endogenous levels of CPI-17 polyclonal Antibody protein only when phosphorylated at Thr38.
Molecular Weight: ~ 22 kDa
Note: For research use only, not for use in diagnostic procedure.
Alternative Names: Protein phosphatase 1 regulatory subunit 14A; 17 kDa PKC-potentiated inhibitory protein of PP1; Protein kinase C-potentiated inhibitor protein of 17 kDa; CPI-17; CPI17; PPP1INL; PPP1R14A
Immunogen: Synthetic phosphopeptide derived from human CPI-17 around the phosphorylation site of Threonine 38.
Conjugate: Unconjugated
Modification: Phosphorylation
Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .
Pathway: Signaling Pathways Activating p38 MAP Kinase,
